FDA Drug Label
SAXENDA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2014
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 50% · Mixed 40% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.05–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 60% said they felt similar to their last entry, 30% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 481 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 47% · Mixed 34% · Unfavorable overall 19%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 1–2 mg · Most common: 0.6–1 mg
Reports span 0.2–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 31 days · Based on 111 repeat reporters
Published sources linked on the Liraglutide and MK-677 wiki pages.
FDA Drug Label
Novo Nordisk. FDA Drug Label. 2014
FDA Drug Label
Novo Nordisk. FDA Drug Label. 2010
PubMed
Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016
PubMed
Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015
PubMed
Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022
PubMed
Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020
PubMed
Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026
PubMed
Murphy MG, Plunkett LM, Gertz BJ, et al. J Clin Endocrinol Metab. 1998
PubMed
Nass R, Pezzoli SS, Oliveri MC, et al. J Clin Endocrinol Metab. 2008
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Murphy MG, Plunkett LM, Gertz BJ, et al. The Journal of clinical endocrinology and metabolism. 1998
PubMed
Philip M, Karakka Kal AK, Subhahar MB, et al. Rapid communications in mass spectrometry : RCM. 2022